Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Govind Ragupathi, Xiaohong Wu, Philip Livingston, Wolfgang Scholz, Christine Kearns and Paul Maffuid
Title Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model
Journal Cancer Research
Abstract Text Cancer Res 2016;76(24 Suppl):Abstract nr A73


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
MVT-5873 HuMab 5B1|HuMab-5B1 MVT-5873 (HuMab-5B1) is an IgG1 antibody that binds to the sialyl Lewis A epitope of CA19-9, which may result in antitumor activity including tumor growth inhibition (Cancer Res 2016;76(24 Suppl):Abstract nr A73, PMID: 32399263).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown pancreatic cancer not applicable Gemcitabine + MVT-5873 + Nab-paclitaxel Preclinical - Cell line xenograft Actionable In a preclinical study, MVT-5873 enhanced efficacy of the combination therapy, Gemzar (gemcitabine) and Abraxane (nab-paclitaxel), in pancreatic xenograft models, demonstrating increased inhibition of tumor growth and greater reduction of tumor volume when compared to single agents (Cancer Res 2016;76(24 Suppl):Abstract nr A73). detail...
Unknown unknown pancreatic cancer not applicable MVT-5873 Preclinical - Cell line xenograft Actionable In a preclinical study, a pancreatic xenograft model demonstrated reduced tumor volume and tumor growth inhibition when treated with MVT-5873 (Cancer Res 2016;76(24 Suppl):Abstract nr A73). detail...